Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221 - Concepedia

Concepedia

Publication | Closed Access

Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221

88

Citations

23

References

2019

Year

Anna V. Tinker, Holger W. Hirte, Diane Provencher, Marcus O. Butler, Heather Ritter, Dongsheng Tu, Hatem A. Azim, Paulo Paralejas, Nathalie Grenier, Shirley-Ann Hahn,

Clinical Cancer Research

Abstract

Monalizumab 10 mg/kg i.v. every 2 week is well tolerated in patients with pretreated gynecologic cancers. Short-term disease stabilization was observed. Future studies should assess combinations with other agents, including immunotherapeutics.

References

	Year	Citations

Page 1